Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
NCT ID: NCT06692881
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
167 participants
OBSERVATIONAL
2025-02-12
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Approximately 167 participants will be enrolled in approximately 10-15 sites across Canada.
Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 12 weeks.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ubrogepant
Participants will receive Ubrogepant as prescribed by their physician in routine clinical practice.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults (≥18 years of age) at time of informed consent.
* Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018).
* Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms
* Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation
* Participants willing and able to comply with the requirements of the study.
* Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access.
Exclusion Criteria
* Participants with history of known contraindications to ubrogepant as per local labeling.
* Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception
* Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies.
* History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Calgary Headache Assessment and Management Program /ID# 271475
Calgary, Alberta, Canada
Burrard Health Center /ID# 271474
Vancouver, British Columbia, Canada
Royal Jubilee Hospital /ID# 271476
Victoria, British Columbia, Canada
Maritime Neurology /ID# 271867
Halifax, Nova Scotia, Canada
Neurocentre of Eastern Ontario /ID# 271865
Kingston, Ontario, Canada
Centricity /ID# 271477
London, Ontario, Canada
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 272031
London, Ontario, Canada
360 Concussion Care /ID# 271972
Ottawa, Ontario, Canada
Bayshore Neurology /ID# 280213
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre /ID# 276844
Toronto, Ontario, Canada
Centre de Recherche St-Louis /ID# 272843
Lévis, Quebec, Canada
Genge Partners /ID# 273302
Montreal, Quebec, Canada
Diex Recherche Sherbrooke /ID# 271677
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P25-245
Identifier Type: -
Identifier Source: org_study_id